SCHEMBL23465352

SCHEMBL23465352

N#C/C(=C\C(=O)O)c1ccc(F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.45
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
APEX1 P27695 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
MAPT P10636 2/20 0.43
BCL2L1 Q07817 1/20 0.42
BAD Q92934 1/20 0.42
LMNA P02545 3/20 0.42
ALDH1A1 P00352 2/20 0.42
ALPG P10696 2/20 0.42
HPGD P15428 2/20 0.41
USP2 O75604 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8743711 1.00 SMN1; SMN2 (0.45) SMN1; SMN2CA1CA2KMT2AMEN1
SCHEMBL22691970 0.85 TSHR (0.48) SMN1; SMN2CA1CA2KMT2APOLB
SCHEMBL28093622 0.83 ESR1 (0.56) CA1CA2KMT2ACES2MAPT
SCHEMBL854364 0.83 ESR1 (0.56) CA1CA2KMT2ACES2MAPT
SCHEMBL28554503 0.83 ESR1 (0.56) CA1CA2KMT2ACES2MAPT
SCHEMBL26827 0.83 ESR1 (0.56) CA1CA2KMT2ACES2MAPT
SCHEMBL670068 0.82 ALDH1A1 (0.46) SMN1; SMN2CA1CA2KMT2AMEN1
SCHEMBL19471869 0.82 ALDH1A1 (0.46) SMN1; SMN2CA1CA2KMT2AMEN1
SCHEMBL305984 0.82 ALDH1A1 (0.46) SMN1; SMN2CA1CA2KMT2AMEN1
Potassium Ion SCHEMBL1471147 0.82 CA1 (0.52) SMN1; SMN2CA1CA2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230023332-A1 OLEAN-PHENYLACRYLAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF LUNAN PHARMACEUTICAL GROUP CORPORATION (CN) 2023-01-26 US disclosed
CN-110256522-B Tripterine cinnamate derivatives, and preparation method and application thereof 中国药科大学 2022-03-08 CN disclosed
WO-2021104391-A1 OLEANANE CINNAMAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF 鲁南制药集团股份有限公司 2021-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230023332-A1 OLEAN-PHENYLACRYLAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF PAOX, ALOX12, PNMT SMN1; SMN2 3856/4885CA1 3861/4885CA2 4233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.